NIBAN2 and breast carcinoma: Cheng et al.23 showed that FAM129B, by interfering with the interaction of the Cul3 substrate adapter, Kelch1, with the substrate Nrf2, elevates Nrf2 protein, suppresses reactive oxygen products and thus make breast cancer cells and colorectal cancer cells more resistant to Oxaliplatin.